Citations

Clear

4610 citation(s) found for "Lu, Brian".

GRADE Certainty Ratings: Thresholds Rather Than Categories of Contextualization (GRADE Guidance 41)
Hultcrantz, Monica , Schünemann, Holger J. , Rind, David M., Tovey, David , Alper, Brian S. , Akl, Elie A. , Saif‐Ur‐Rahman, KM , Sousa‐Pinto, Bernardo , Mustafa, Reem A , Mayer, Martin , Tovey, David , Alper, Brian S , Akl, Elie A , Saif-Ur-Rahman, K M , Schünemann, Holger J , Murad, M. Hassan , Neumann, Ignacio , Izcovich, Ariel , Guyatt, Gordon

Mayo Clinic

Annals of Internal Medicine | June 30, 2025 | Volume: 178 | Issue: 8 | Pages: 1183-1186

10.7326/annals-25-00548 | PMID 40587852 Get It

Measurable residual disease (MRD) as a surrogate end point for clinical drug approval in acute myeloid leukemia (AML): Perspectives from the MRD Partnership and Alliance in AML Clinical Treatment Consortium
Boyiadzis, Michael , Wei, Andrew H. , Freeman, Sylvie , Chyla, Brenda , Hersey, Sarah, Patel, Reshma, Maloney, Brian, Zumofen, Marie-Hélène Blanchet , Hoef, Marlies Van, Wulff, Beate, Obourn, Vanessa, Patel, Shalaka, Menezes, Daniel L. , Bengoudifa, Bourras‐Rezki, Dimier, Natalie , Wei, Andrew H , Paiva, Bruno , Kaspers, Gertjan J.L. , Shi, Qian , Prior, Thomas J. , Roboz, Gail J. , Prébet, Thomas

Mayo Clinic

Cancer | June 27, 2025 | Volume: 131 | Issue: 13 | Pages: No page available

10.1002/cncr.35960 | PMID 40576165 Get It

AbstractDespite advances in acute myeloid leukemia (AML) treatment, significant unmet medical needs remain. Surrogate end points for overall survival can accelerate the approval of novel therapies. Measurable residual disease (MRD) is a promising surrogate end point candidate, providing a sensitive and quantitative assessment of disease burden. Numerous studies have demonstrated that negative MRD status—across diverse methodologies, assessment timepoints and thresholds, patient subgroups, and clinical settings—independently predicts improved survival. Although MRD can inform therapeutic decisions at the patient level, its formal integration as a primary surrogate end point in regulatory frameworks for clinical trials requires rigorous validation. MRD Partnership and Alliance in AML Clinical Treatment (MPAACT) is a research consortium among industry and academic leaders. MPAACT actively engages with regulatory agencies, health technology assessment bodies, technology vendors, and patient groups to establish a pathway for validating MRD as a surrogate end point in AML clinical trials. For the current article, the authors reviewed the status of MRD assessment, its use in recent clinical trials, current MRD assessment methodologies, standardization, regulatory guidance, statistical approaches, and patient access considerations necessary for MRD to become a surrogate clinical trial end point. The extensive collaboration between MPAACT, global industry, and academic partners—including data sharing and resource integration—underscores the collective commitment to advancing AML therapies. Establishing MRD as a surrogate end point could accelerate the development and approval of innovative treatments, ultimately improving patient outcomes.
BraTS-PEDs: Results of the Multi-Consortium International Pediatric Brain Tumor Segmentation Challenge 2023
Kazerooni, Anahita Fathi , Khalili, Nastaran, Liu, Xinyang , Jiang, Zhifan , Pavaine, Julija , Jones, Blaise V. , Sheth, Nakul , McAllister, Aaron S. , Tu, Wenxin , Rodriguez, Andres Fernandez, Shaikh, Ibraheem S , Sanchez-Montano, Mariana , Lai, Hollie Anne , Adewole, Maruf , Albrecht, Jake, Anazodo, Udunna, Anwar, Syed Muhammed, Aristizábal, Alejandro , Baid, Ujjwal , Bergquist, Timothy , Conte, Gian-Marco, Eddy, James A. , Ezhov, Ivan , Gandhi, Deep , Gottipati, Anurag , Haldar, Shuvanjan, Janas, Anastasia , Elaine, Elaine, Karargyris, Alexandros , Kassem, Hasan, Khalili, Neda , Maleki, Nazanin , Meier, Zeke, Saluja, Rachit , Sheller, Micah , Shinohara, Russell Takeshi, Viswanathan, Karthik , Wang, Chunhao , Storm, Phillip B. , Packer, Roger, Hummel, Trent R. , Hoffman, Lindsey M. , Nabavizadeh, Ali , Ware, Jeffrey B., Rood, Brian , Resnick, Adam J., Linguraru, Marius George , Khalili, Nastaran, Haldar, Debanjan , Zapaishchykova, Anna , Shah, Lubdha M. , Prabhu, Sanjay P. , Nandolia, Khanak , Anderson, Hannah, Bagheri, Sina , Borja, Austin J. , Calabrese, Evan , Chung, Verena , Familiar, Ariana , Farahani, Keyvan , Iglesias, Juan Eugenio , Kofler, Florian , LaBella, Dominic , Leemput, Koen Van , Li, Hongwei , Meier, Zeke, Menze, Bjoern H. , Moawad, Ahmed W. , Pati, Sarthak , Piraud, Marie , Poussaint, Tina Young , Reitman, Zachary J. , Rudie, Jeffrey D. , Shinohara, Russell Taki , Wiestler, Benedikt , Wiggins, Walter F. , Davatzikos, Christos , Bornhorst, Miriam , Blank, Peter M K de , Aboian, Mariam , Kann, Benjamin H. , Bakas, Spyridon , Vossough, Arastoo

Mayo Clinic

Machine Learning for Biomedical Imaging | June 26, 2025 | Volume: 3 | Issue: June 2025 | Pages: 72-87

10.59275/j.melba.2025-f6fg Get It

Pediatric central nervous system tumors are the leading cause of cancer-related deaths in children. The five-year survival rate for high-grade glioma in children is less than 20%. The development of new treatments is dependent upon multi-institutional collaborative clinical trials requiring reproducible and accurate centralized response assessment. We present the results of the BraTS-PEDs 2023 challenge, the first Brain Tumor Segmentation (BraTS) challenge focused on pediatric brain tumors. This challenge utilized data acquired from multiple international consortia dedicated to pediatric neuro-oncology and clinical trials. BraTS-PEDs 2023 aimed to evaluate volumetric segmentation algorithms for pediatric brain gliomas from magnetic resonance imaging using standardized quantitative performance evaluation metrics employed across the BraTS 2023 challenges. The top-performing AI approaches for pediatric tumor analysis included ensembles of nnU-Net and Swin UNETR, Auto3DSeg, or nnU-Net with a self-supervised framework. The BraTS-PEDs 2023 challenge fostered collaboration between clinicians (neuro-oncologists, neuroradiologists) and AI/imaging scientists, promoting faster data sharing and the development of automated volumetric analysis techniques. These advancements could significantly benefit clinical trials and improve the care of children with brain tumors.
Efficacy and safety of thrombolysis for pediatric venous thromboembolism: a systematic review and meta-analysis
Kawtharany, Hassan , Azzam, Muayad , Alkhader, Aseel, Betensky, Marisol , Hamarsha, Qais, Mansour, Razan , Tabak, Carine , Bhat, Rukhmi , Biss, Tina , Brandão, Leonardo R. , Chan, Anthony K.C. , Faustino, E. Vincent S. , Jaffray, Julie , Jones, Sophie , Kerlin, Bryce A. , Pelland‐Marcotte, Marie‐Claude , Raulji, Chittalsinh M , Sartain, Sarah E. , Ommen, C. Heleen van , Wiernikowski, John , Williams, Suzan , Wilson, Hope P. , Woods, Gary , Zia, Ayesha , Abou Zeid, Hadi K, Brandão, Leonardo R , Chan, Anthony K C , Jaffray, Julie , Jones, Sophie , Kerlin, Bryce A , Kucine, Nicole , Male, Christoph , Pelland-Marcotte, Marie-Claude , Raffini, Leslie , Raulji, Chittalsinh M , Tarango, Cristina , van Ommen, C Heleen , Velez, Maria C , Vesely, Sara K , Zia, Ayesha , Monagle, Paul , Mustafa, Reem A , Kawtharany, Hassan , Hamarsha, Qais , Zeid, Hadi Khaled Abou , Patel, Payal Mukesh , Baghdadi, Sarah L., Bercovitz, Rachel S. , Branchford, Brian R. , Kumar, Riten , Takemoto, Clifford M.

Mayo Clinic

Blood Advances | June 25, 2025 | Volume: 9 | Issue: 21 | Pages: 5512-5527

10.1182/bloodadvances.2025017058 | PMID 40561511 Get It

Abstract We conducted this systematic review to evaluate outcomes of thrombolysis followed by anticoagulation vs anticoagulation alone in pediatric patients with venous thromboembolism (VTE). This systematic review addresses mortality, VTE resolution, recurrence, bleeding, and organ-specific outcomes in 5 PICO (population, intervention, comparison, outcomes) questions on thrombolysis across pulmonary embolism (PE), extremity deep vein thrombosis (DVT), right atrial thrombosis (RAT), cerebral sinus venous thrombosis (CSVT), and renal vein thrombosis (RVT). Meta-analysis reported risk ratios or differences (95% confidence intervals [CIs]), and absolute effects per 1000 patients. Certainty of evidence was assessed using GRADE (Grading of recommendation, assessment, Development, and Evaluation) guidelines. Thirteen nonrandomized studies were included and no randomized clinical trials addressed these questions. Thrombolysis might be associated with a higher risk of major bleeding, clinically relevant nonmajor bleeding, or unspecified bleeding with risk differences of 0.09 (95% CI, −0.06 to 0.23), 0.06 (95% CI, −0.11 to 0.22), and 0.09 (95% CI, −0.04 to 0.23), respectively. In PE with hemodynamic compromise, thrombolysis might be associated with a lower risk of mortality but conclusions on PE progression were uncertain in submassive PE. In DVT, thrombolysis may have little to no effect on mortality or thrombus resolution but might be associated with lower risk of postthrombotic syndrome. In RAT, thrombolysis might have little to no effect on thrombus resolution but a higher risk of major bleeding and mortality. For CSVT and RVT, the evidence was very limited. These findings were based on very-low-certainty evidence because of confounding and imprecision from small sample sizes. This systematic review highlights key challenges in developing recommendations for thrombolysis in children with VTE.
Consensus guideline for the management of gastric cancer with synchronous peritoneal metastases
Butensky, Samuel D. , Bansal, Varun , Su, David , Waheed, Muhammad Talha , Nikiforchin, Andrei , Gomez‐Mayorga, Jorge L. , Radomski, Shannon N. , Sun, Beatrice J. , Turaga, Kiran K. , Gunderson, Craig G. , Lacy, Jill , In, Haejin, Kennedy, Timothy J., Yoon, Harry H. , Sundar, Raghav , Ly, Quan P. , Fackche, Nadege , Chan, Carlos H.F. , Maron, Steven B. , Hoehn, Richard S. , Bansal, Varun V , Su, David G , Radomski, Shannon N , Turaga, Kiran K , Badgwell, Brian D , Yoon, Harry H , Chan, Carlos H F , Hoehn, Richard , Olecki, Elizabeth Josephine , Badgwell, Brian D. , In, Haejin , Greer, Jonathan B. , Woo, Yanghee

Mayo Clinic

Cancer | June 25, 2025 | Volume: 131 | Issue: 13 | Pages: No page available

10.1002/cncr.35870 | PMID 40558029 Get It

AbstractBackgroundGastric cancer with synchronous peritoneal metastases is a debilitating disease with limited treatment options. This article describes an update of the 2018 Chicago Consensus guidelines addressing the management of gastric cancer with synchronous peritoneal metastases in line with the most recent evidence.MethodsA clinical management pathway was updated through two rounds of a Delphi consensus to assess agreement levels with pathway blocks. Supporting evidence underwent evaluation using a rapid literature review. Meta‐analyses were performed as appropriate.ResultsOverall, the level of evidence in this disease subset was low to moderate. Of 124 participants in the first round, 109 (88%) responded in the second round. Strong consensus (>90%) was achieved in six of eight blocks (75%) in rounds 1 and 2. A multidisciplinary preoperative assessment and diagnostic laparoscopy should be offered to all patients, whereas patients with a high burden of disease or progression should undergo nonsurgical management. Patients with stable/responsive disease and a low peritoneal carcinomatosis index should subsequently be offered treatment with regional therapeutic interventions and cytoreductive surgery. In patients who are cytology‐positive, systemic therapy can be used to convert them to cytology‐negative, with subsequent surgery offered according to the patient's goals of care. Meta‐analysis of observational and randomized control trials revealed a survival benefit with the addition of intraperitoneal chemotherapy to cytoreductive surgery (hazard ratio, 0.52).ConclusionsThe consensus‐driven clinical pathway for gastric cancer with synchronous peritoneal metastases offers vital clinical guidance for practitioners. There is a growing body of high‐quality evidence to support management strategies, and future clinical trials are eagerly awaited.
The hope and the hype of artificial intelligence for syncope management
Johnston, Samuel L. , Barsotti, Ercole John , Fedorowski, Artur , Ricci, Fabrizio , Heller, Eric G, Sheldon, Robert S. , Sutton, Richard , Shen, Win‐Kuang , Thiruganasambandamoorthy, Venkatesh , Adhaduk, Mehul , Parker, William H. , Aburizik, Arwa , Haselton, Corey R, Cuskey, Alex J, Johansson, Madeleine , Dominic, Paari , Rao, B. Hygriv , Mudireddy, Avinash , Statz, Giselle M., Benditt, David G. , Gatti, Mauro , Menè, Roberto , Shiffer, Dana , Vassilikos, Vassilios , Bakogiannis, Constantinos , Fedorowski, Artur , Ricci, Fabrizio , Sheldon, Robert , Sutton, Richard , Shen, Win-Kuang , Thiruganasambandamoorthy, Venkatesh , Adhaduk, Mehul , Parker, William H , Aburizik, Arwa , Lee, Sangil , Johansson, Madeleine , Macfarlane, Donald , Dominic, Paari , Abe, Haruhiko , Rao, B Hygriv , Mudireddy, Avinash , Sonka, Milan , Sandhu, Roopinder K , Kenny, Rose Anne , Gopinathannair, Rakesh , Benditt, David , Dipaola, Franca , Gatti, Mauro , Giaj Levra, Alessandro , Furlan, Raffaello , Ruwald, Martin H , Vassilikos, Vassilios , Gebska, Milena A , Olshansky, Brian , Cuskey, Alex, Lee, Sangil , Kenny, Rose Anne , Gopinathannair, Rakesh , Dipaola, Franca , Costantino, Giorgio , Furlan, Raffaello , Olshansky, Brian

Mayo Clinic

European Heart Journal - Digital Health | June 25, 2025 | Volume: 6 | Issue: 5 | Pages: 1046-1054

10.1093/ehjdh/ztaf061 | PMID 40984999 Get It

Abstract Aims Syncope remains a diagnostic challenge despite advancements in testing and treatment. Cardiac syncope is an independent predictor of mortality and can be difficult to distinguish from other causes of transient loss of consciousness (TLOC). This paper explores whether artificial intelligence (AI) can improve the evaluation and management of patients with syncope. Methods and results We conducted a literature review and incorporated the opinions of experts in the fields of syncope and AI. The cause of TLOC is often unclear, hospitalization criteria are ambiguous, diagnostic tests are frequently non-informative, and assessments are costly. Patients are left with unanswered questions and limited guidance. Artificial intelligence (AI) has the potential to optimize syncope evaluation by processing large data sets, detecting imperceptible patterns, and assisting clinicians. However, AI has limitations, including errors, lack of human empathy, and uncertain clinical utility. Liability issues further complicate its integration. We present three viewpoints: (i) AI is crucial for advancing syncope management; (ii) AI can enhance the patient experience; and (iii) AI in syncope care is inevitable. Conclusion Artificial intelligence may improve syncope diagnosis and management, particularly through machine learning–based test interpretation and wearable device data. However, it has yet to surpass human clinical judgment in complex decision-making. Current challenges include gaps in understanding syncope mechanisms, AI interpretability, generalizability, and clinical integration. Standardized diagnostic approaches, real-world validation, and curated data sets are essential for progress. Artificial intelligence may enhance efficiency and communication but raises concerns regarding confidentiality, bias, inequities, and legal implications.
Clinical use and reporting of neurofilament quantification in neurological disorders: A global overview
Delaby, Constance , Martinez‐Yriarte, Jose, Zecca, Chiara , Körtvelyessy, Péter , Tumani, Hayrettin , Quadrio, Isabelle , Hart, Melanie , Olsen, Dorte Aalund , Alcolea, Daniel, Blennow, Kaj , Bouaziz-Amar, Élodie , Baldeiras, Inês , Bigot‐Corbel, Edith , Bjerke, Maria , Perez, Mercedes Carretero, Chabrashvili, Tinatin, Chapman, Miles, Fourier, Anthony , Galimberti, Daniela , Gezen‐Ak, Duygu , Gouju, Julien , Flórez, Silvia de las Heras , Sanchez, Juanjo Hernandez, Herwerth, Marina , Imperiale, Daniele , Kaczorowski, Flora, Keshavan, Ashvini , Leithner, Christoph , Blanc, M, Rodríguez, Jose Enrique Martínez, Musso, Giulia , Nogueira, Léonor, Garay, Raquel Perez, Quillard‐Muraine, Muriel, Borja, Enrique Rodriguez, Schraen, Susanna, Terracciano, Daniela , Bachhuber, Franziska , Tzartos, Socrates J., Tzartos, John , Unterwalder, Nadine, Lehmann, Sylvain , Keshavan, Ashvini , Galimberti, Daniela , Herwerth, Marina , Ladang, Aurélie , Logroscino, Giancarlo , Tumani, Hayrettin , Parchi, Piero , Alcolea, Daniel , Fortea, Juan , Lleó, Alberto , Algeciras‐Schimnich, Alicia , Ayrignac, Xavier , Bedel, Aurélie , Santos, Gustavo Alves Andrade dos , Borelli, Wyllians Vendramini , Perez, Mercedes Carretero, Casoli, Tiziana , Cusato, Jessica , Dursun, Erdinç , Gordon, Brian A. , Sanchez, Juanjo Hernandez, Kasuga, Kensaku , Khalil, Michael , Kühle, Jens , Lewczuk, Piotr , Letournel, Franck , Tsolaki, Magda , Giuffrè, Guido Maria , Mroczko, Barbara , Kulczyńska‐Przybik, Agnieszka , Paquet, Claire , Baiardi, Simone , Gaetani, Lorenzo , Parnetti, Lucilla , Poesen, Koen , Halbgebauer, Steffen , Vermunt, Lisa , Wellington, Cheryl L. , Zetterberg, Henrik , Teunissen, Charlotte E.

Mayo Clinic

Alzheimer's & Dementia | June 23, 2025 | Volume: 21 | Issue: 6 | Pages: No page available

10.1002/alz.70343 | PMID 40551293 Get It

Abstract INTRODUCTION Neurofilament light chain (NfL) quantification aids in diagnosing and predicting neurological disorders, but clinical and laboratory practices vary across centers. Differences in result interpretation and reporting further challenge test commutability. This study aimed to review the global analytical and post‐analytical methods used for NfL measurement in routine clinical practice across different contexts. METHODS We established an international working group (WG) and distributed a survey to its members to gather information on context of use (COU), (pre) analytical methods, cutoff usage, as well as the interpretation and reporting of NfL measurements. RESULTS Among the centers, 63% measured NfL in cerebrospinal fluid (CSF), 87% in blood, and 53% in both. COU was widespread, with 50% defining pathological cutoffs based on publications and 42% considering age. Reporting was primarily done through numeric results (95%). DISCUSSION Harmonizing cutoffs, reporting, and interpretation across various clinical contexts will facilitate the incorporation of this biomarker into routine clinical practice. Highlights Unique international overview of current analytical and post‐analytical methods for neurofilament light chain (NfL) measurement in routine clinical practice. Tailored sheets for each neurological application. Strategies to harmonize cutoffs, reporting, and interpretation of NfL's measurement.
Medications for Weight Loss and MASLD
Asgharpour, Amon , Aby, Elizabeth S. , Mellinger, Jessica L. , Luther, Jay , Izzy, Manhal , Haque, Lamia , Lee, Brian T. , Sherman, Courtney B. , Rice, John P. , Chandna, Shaun , Chen, Po‐Hung , Singal, Ashwani K. , Bansal, Meena B. , Cotter, Thomas G. , Im, Gene , Cotter, T G , Stine, Jonathan G. , Jophlin, Loretta , Goel, Aparna , Lizaola‐Mayo, Blanca

Mayo Clinic

Journal of Clinical Gastroenterology | June 23, 2025 | Volume: 60 | Issue: 8 | Pages: 750-757

10.1097/mcg.0000000000002147 | PMID 40549581 Get It

Goals: Our aim was to perform a national survey of provider attitudes, practices, and knowledge regarding weight loss and MASLD medications in patients with MASLD. Background: While weight loss is a cornerstone in the management of metabolic dysfunction-associated steatotic liver disease (MASLD), FDA-approved medications for weight loss remain underutilized. Results: We conducted a survey before resmetirom approval of hepatology and gastroenterology providers practicing in 44 states. Surveys were sent to 747 providers with 304 complete responses (41%), of whom 260 (86%) work at a liver transplant center. While nearly all respondents (96%) believed that weight loss medications could benefit patients with MASLD, 77% have never/rarely prescribed them due to low comfort (81%). Among weight loss medication prescribers, glucagon-like peptide-1 (GLP-1) receptor agonists were preferred (66%). In contrast, 63% had prescribed off-label medications for MASLD in the past 12 months, most commonly vitamin E (30%) and GLP-1 receptor agonists (25%). The top reported barriers to prescribing weight loss medications were lack of training/unfamiliarity, cost/insurance coverage, and side-effects, which may be explained by low formal obesity education and lack of knowledge (only 33% of FDA-approved medications for weight loss were correctly identified by >50% of providers). Overall, there was reasonable provider-reported adherence to the 2023 AASLD practice guidance for MASLD. Conclusions: This nationwide survey of hepatology and gastroenterology providers before resmetirom demonstrates that while off-label prescribing for MASLD was common, weight loss medication prescription rates remain very low due to low comfort possibly from insufficient education despite strong beliefs that they can benefit patients with MASLD.